May 2022 Update: BioGX in silico analysis of SARS-CoV-2 Variants of Concern

BioGX continuously monitors the evolution of COVID-19 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants without impacting performance.

 

BioGX has completed in-silico analysis of over 2.5 million SARS-CoV-2 genome sequences available as of May 31, 2022. Sequence analysis compared the available Omicron genomes against the SARS-CoV-2 nucleocapsid (N-gene) and envelope (E-gene) , targeted by BioGX products. In-silico analysis and empirical testing of the Omicron variant confirmed the gene mutations will not affect the performance of the BioGX portfolio of SARS-CoV-2 products.

 

BioGX portfolio of SARS-CoV-2 products

  1. BioGX Xfree™ COVID-19 Direct RT-PCR – FDA EUA
  2. BD BioGX SARS-CoV-2 Reagents for BD MAX™ System
  3. BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex
  4. BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™
  5. BioGX SARS-CoV-2 N1, N2, E-gene (RUO)
  6. BioGX SARS-CoV-2 N1, Flu A, Flu B, RSV A/B (RUO)

 

U.S. CDC and WHO Variants of Concern* % Clades detected by targets
WHO designationPango lineageGISAID

clade 

Nextstrain cladeSpike Protein 

(a.a. changes)

Region Initially Documented (Date)No. Sequences Analyzed 

(Date)

N1N2E
AlphaB.1.1.7

Q.x

GRY20I (V1)69del, 70del, 144del, (E484K**),(S494P**),N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, (K1191N**)United Kingdom (SEP 2020)430,915

(31MAY2022)

>99%
BetaB.1.351

B.1.351.2

B.1.351.3

GH/501Y.V220H (V2)L18F, D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701VSouth Africa (MAY 2020)26,248

(31MAY2022)

>99%
GammaP.1

P.1.x

GR/501Y.V320J (V3)681H,L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027IBrazil

(NOV 2020)

82,494

(31MAY2022)

>99%
DeltaB.1.617.2

AY.x

G/478K.V121A, 21I, 21J417N, T19R, (V70F**), T95I, G142D, E156-, F157-, R158G, (A222V**), (W258L**), (K417N**), L452R, T478K, D614G, P681R, D950NIndia

(OCT 2020)

1,690,105

(31MAY2022)

>99%
OmicronB.1.529

BA.x☨

GR/484A21K, 21L, 21M+R346KMultiple Countries

(NOV 2021)

457,058

(31MAY2022)

>99%

 

*Variants of concern being monitored by US CDC and WHO

**Present in a subset of sequences

BA.1, BA.2, BA.3, BA.4, BA.5, and XE are sub-lineages of Omicron variant